(Press-News.org) Women with ovarian cancer that has recurred after chemotherapy have survived for longer after treatment with a biological therapy called cediranib, according to new results to be presented today (Monday) at the 2013 European Cancer Congress (ECC2013) [1].
Cediranib, which is taken in pill form, is an inhibitor of a cell signalling process involved in formation of tumour blood vessels, essential for tumour growth, and it is the first oral inhibitor of its kind to show an improvement in the time before patients' disease progresses and in overall survival. The drug is a tyrosine kinase inhibitor, a type of biological therapy that blocks vascular endothelial growth factor (VEGF) receptors, which control the development of blood vessels required for growing tumours.
Professor Jonathan Ledermann, Professor of Medical Oncology at UCL Cancer Institute, University College London, presented first results from ICON6, an international randomised, double-blind, academic clinical phase III trial of cediranib.
"In women whose ovarian cancer had been treated with platinum-based chemotherapy together with cediranib given during and after the chemotherapy, we found that the time before the tumour started to grow again was extended by an average of 3.2 months. This sounds like a modest increase but represents about a 30% improvement, with overall survival also increased by a similar amount, to an average of 2.7 months over a two-year period of follow-up," he said.
Studies with chemotherapy alone have shown that the time before patients experience disease progression following treatment for a relapse that is sensitive to platinum-based chemotherapy is an average of eight to nine months. These latest results show that cediranib in addition to chemotherapy increased the time before the disease progressed from 9.4 to 12.6 months over a period of two years, and it extended overall survival from 17.6 to 20.3 months.
"These are ground-breaking data," said Prof Ledermann. "Cediranib is the first oral VEGF tyrosine kinase inhibitor that has been shown to delay tumour progression and improve overall survival in recurrent ovarian cancer. It is simple to give for a prolonged period and in most patients it is well-tolerated." Adverse side-effects included high blood pressure, diarrhoea and fatigue.
A total of 456 patients whose ovarian cancer had recurred were enrolled in the trial in 63 centres from the UK, Canada, Australasia and Spain. They were randomised to receive platinum-based chemotherapy together with a placebo (the reference arm of the trial), or 20 mg a day of cediranib during chemotherapy followed by placebo for 18 months (concurrent arm of the trial), or 20 mg a day of cediranib during chemotherapy followed by cediranib as a maintenance treatment (maintenance arm).
"ICON6 has a three-arm design in which the effect of cediranib given with chemotherapy and continued as maintenance can be compared with standard chemotherapy. This is the first trial to have demonstrated a benefit of concurrent cediranib with chemotherapy, as well as demonstrating an additional benefit with maintenance cediranib," he said.
An increased survival time of nearly three months is significant in this group of patients. Prof Ledermann explained: "In previous ovarian cancer trials any improvement seen with each new treatment has been incremental. Survival has improved through sequential use of drugs. Most of the recent positive trials have shown an improvement in progression-free survival. Trials showing an improvement in overall survival are uncommon. Cediranib produces an incremental improvement in progression-free survival and an incremental improvement in overall survival. Although the average improvement in overall survival is 2.7 months, some patients will see a much more substantial benefit."
ECCO president, Professor Cornelis van de Velde, commented: "These are important results for women with recurrent ovarian cancer. Once the disease has recurred there are few treatment options available that make a significant difference to its progression and to overall survival. The ICON6 trial shows that cediranib does make a difference and it is to be hoped that it can be made available to women as soon as is practicable."
###
[1] The 2013 European Cancer Congress is the 17th congress of the European CanCer Organisation (ECCO), the 38th congress of the European Society for Medical Oncology (ESMO) and the 32nd congress of European Society for Therapeutic Radiology and Oncology (ESTRO).
[2] ICON6 is an academic trial run by the UK Medical Research Council's Clinical Trials Unit, funded by Cancer Research UK, and supported by AstraZeneca. It is a Gynecologic Cancer Intergroup (GCIG) trial with participating groups from UK (NCRI and SGCTG), Canada (NCIC Clinical Trials Group), Australia/New Zealand (ANZGOG) and Spain (GEICO).
[3] Cediranib is an investigational compound manufactured by AstraZeneca and is not currently approved for use in the European Union or United States.
Biological therapy with cediranib improves survival in women with recurrent ovarian cancer
2013-09-30
ELSE PRESS RELEASES FROM THIS DATE:
Olympians say poor oral health is impairing performance
2013-09-30
Many of the elite sportsmen and women who competed at the London 2012 Olympic Games had poor levels of oral health similar to those experienced by the most disadvantaged populations. 18 per cent of athletes surveyed said their oral health was having a negative impact on their performance.
The research, which was led by Professor Ian Needleman at the UCL Eastman Dental Institute, is published in the British Journal of Sports Medicine.
The researchers recruited 302 athletes to take part in the study at the Dental Clinic in the London 2012 athletes' village. The athletes ...
Quantum computers: Trust is good, proof is better
2013-09-30
This news release is available in German. The harnessing of quantum phenomena, such as superposition and entanglement, holds great promise for constructing future supercomputers using quantum technology. One huge advantage of such quantum computers is that they are capable of performing a variety of tasks much quicker than their conventional counterparts. The use of quantum computers for these purposes raises a significant challenge: how can one verify the results provided by a quantum computer?
It is only recently that theoretical developments have provided methods ...
And in the beginning was histone 1
2013-09-30
A zygote is the first cell of a new individual that comes about as the result of the fusion of an ovule with a spermatozoid. The DNA of the zygote holds all the information required to generate an adult organism. However, in the first stages of life, during the so-called embryogenesis, the genome of this zygote is repressed and does not exert any activity.
In the fly Drosophila melanogaster, the genomes of the zygote are repressed until the thirteenth division, after which the embryo starts to express its own genes. Headed by Ferran Azorín, also CSIC Research professor, ...
The State of Oncology 2013
2013-09-30
A proposal for a new financing model to tackle the major disparities that exist in the prevention, diagnosis, treatment and outcome of cancer in countries worldwide has been presented at the 2013 European Cancer Congress (ECCO 2013). While much progress has been made against cancer over the last century, a new report brings together evidence that not every patient benefits from it, nor even has the opportunity to benefit. The economics of cancer are daunting and the current model of financing is broken, said Professor Peter Boyle, President of the International Prevention ...
How does divorce affect a man's health?
2013-09-30
New Rochelle, NY, September 30, 2013—Divorced men have higher rates of mortality, substance abuse, depression, and lack of social support, according to a new article in Journal of Men's Health, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers. The article provides assessment and treatment recommendations for care providers and is available free on the Journal of Men's Health website at http://www.liebertpub.com/jmh.
Authors Daniel S. Felix, PhD, University of Nebraska-Lincoln, W. David Robinson, PhD, Utah State University, Logan, and Kimberly J. Jarzynka, ...
New technique helps biologists save the world's threatened seagrass meadows
2013-09-30
Danish and Australian biologists have developed a technique to determine if seagrass contain sulfur. If the seagrass contains sulfur, it is an indication that the seabed is stressed and that the water environment is threatened. The technique will help biologists all over the world in their effort to save the world's seagrass meadows.
Seagrass meadows, such as eelgrass or Halophila, grow along most of the world's coasts where they provide important habitats for a wide variety of life forms. However in many places seagrass meadows have been lost or seriously diminished ...
Atherosclerosis: The Janus-like nature of JAM-A
2013-09-30
A new study by Ludwig-Maximilians-Universitaet (LMU) in Munich researchers led by Christian Weber sheds light on the role of the adhesion molecule JAM-A in the recruitment of immune cells to the inner layer of arteries – which promotes the development of atherosclerosis.
Multiphoton microscopy makes it possible to image the vessel wall (blue: collagen) and inner lining of an artery that has been subjected to atherosclerosis-promoting conditions. Staining for endothelial cells (red) and JAM-A (green) reveals the localization of JAM-A at the cell junctions and the first ...
Testosterone promotes reciprocity in the absence of competition
2013-09-30
Boosting testosterone can promote generosity, but only when there is no threat of competition, according to new research published in Psychological Science, a journal of the Association for Psychological Science. The findings show that testosterone is implicated in behaviors that help to foster and maintain social relationships, indicating that its effects are more nuanced than previously thought.
"Testosterone may mediate competitive and potentially antisocial behavior when social challenges or threats need to be confronted and handled," explains lead researcher Maarten ...
First global study confirms widely held practices on science, math, & reading education
2013-09-30
Chestnut Hill, MA (September 30, 2013) - It's a long held belief that parental and administrative support helps breed academic success; now there's data to back that up. A new study released today by the IEA and the TIMSS and PIRLS International Study Center at Boston College examines what makes up "cultural educational excellence" while quantifying the strengths of best practices at school, and at home.
"The data supports many long held beliefs about good ways of raising your children and preparing them for school," says Dr. Michael Martin of Boston College, co-executive ...
NASA image sees eye in deadly Typhoon Wutip on landfall approach
2013-09-30
NASA's Terra satellite passed over Typhoon Wutip on its approach to a landfall in Vietnam and a visible image revealed its 10-mile-wide eye, and large extent. Wutip was making landfall near Dong Hoi Vietnam around 0900 UTC/5 a.m. EDT.
On Sept. 30 at 03:35 UTC/Sept. 29 at 11:35 p.m. EDT, the Moderate Resolution Imaging Spectroradiometer or MODIS instrument that flies aboard NASA's Terra satellite took a visible image of Typhoon Wutip, clearly showing its eye. At that time, Wutip was still approaching landfall in Vietnam and the heaviest rainfall and strongest thunderstorms ...